Perrigo Company PLC (PRGO)
Days of sales outstanding (DSO)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Receivables turnover | — | — | — | — | — | |
DSO | days | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The days of sales outstanding (DSO) ratio for Perrigo Company PLC has been consistent at "— days" from December 31, 2020, to December 31, 2024, indicating that the company is able to collect its accounts receivable swiftly. While a stable or decreasing DSO is generally positive as it suggests efficient receivables management, a DSO that is too low may imply overly aggressive collection practices. Further analysis of Perrigo's receivables turnover and credit policies could provide additional insights into its overall financial health and working capital management.
Peer comparison
Dec 31, 2024
Company name
Symbol
DSO
Perrigo Company PLC
PRGO
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
90.15
Amphastar P
AMPH
67.96
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
7.07
Biomarin Pharmaceutical Inc
BMRN
84.73
Bristol-Myers Squibb Company
BMY
81.21
Catalyst Pharmaceuticals Inc
CPRX
—